CD274 and melanoma: CMP-001, a CpG-ODN encapsulated in virus-like particles (VLPs) to enhance stability, is currently being evaluated as monotherapy and in combination with pembrolizumab in patients with PD-L1 inhibitor-refractory advanced melanoma.